Novartis is going after a $5 billion market with a new treatment for vision loss. That's a big threat to Regeneron

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 51%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

Novartis' drug brolucizumab just showed that it wasn't any worse than Eylea, a drug from Regeneron, at treating an eye disease.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 729. in BE
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

J&J announces $5 billion share buyback program after report wipes out $50 billion in market valueJohnson & Johnson plans to repurchase $5 billion in shares after the company lost more than $50 billion in market value over two trading days following a scathing news report Friday claiming J&J knew its talc baby powders contained asbestos. Using the money from remorseless trump and remorseless Republicans they gave corporations in 2016 tax scam ! Asbestos isn't safe though. 1/7 men experience prostate in their lifetimes. This product has been around like 47 years. The uptick of prostate cancer correlates. They've lied about asbestos in the talcum. We will never know the disastrous effects this has caused the world. Scrambling to boost the share price of their executive stock options. What a wise use of R&D capital.
La source: CNBC - 🏆 12. / 72 Lire la suite »

Art market faces big test as $2 billion worth of artwork goes up for auctionIt is the biggest auction week of the year, and the biggest test for the art market. Check out the paintings expected to sell for tens of millions of dollars apiece, some of which could set records. 🤮🤮🤮
La source: CNBC - 🏆 12. / 72 Lire la suite »